The Oncology Pharmacist
Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".
First Name *
Last Name *
Email Address *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

  • Home
  • Issues
    • 2020
      • November 2020, Vol 13, No 6
      • September 2020 - Vol 13 no 5
      • July 2020 - Vol 13 no 4
      • May 2020 - Vol 13 no 3
      • March 2020 - Vol 13 no 2
      • January 2020 - Vol 13 No 1
    • 2019
      • November 2019 - Vol 12 No 4
      • August 2019 - Vol 12 No 3
      • May 2019 - Vol 12 No 2
      • February 2019 - Vol 12 No 1
    • 2018
      • November 2018 - Vol 11 No 3
      • August 2018 - Vol 11 No 2
      • May 2018 - Vol 11 No 1
    • Issue Archive
  • Special Issues
    • Supplements
    • Guide to New FDA Approvals
      • 2019 Fourth Annual Guide
      • 2018 Third Annual Guide
      • 2017 Second Annual Guide
      • 2016 First Annual Guide
  • Categories
  • Conference Correspondent
    • Year End Review 2019
  • Web Exclusives
    • Ovarian Cancer Overview
    • All Web Exclusives
    • Drug Updates
    • FDA Approvals, News & Updates
    • In the News
    • Interview with the Innovators
    • Press Releases
    • Online First
    • Media Library
      • Videos
      • Audiocasts
  • Quick Quiz
  • CE
  • About
    • About TOP
    • Advertise
    • Editorial Board
    • Contact Us
    • Resources
    • Submit
      • Author Guidelines
The Oncology Pharmacist

Hope S. Rugo, MD

Professor of Medicine
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Authored Items
HR+/HER2- Metastatic Breast Cancer: Common Presenting Symptoms
Hope S. Rugo, MD
Videos in Breast Cancer, Video
CDK4/6 Inhibitors vs Chemotherapy for Patients with Metastatic Breast Cancer
Hope S. Rugo, MD
Conference Correspondent  in Breast Cancer, Video, SABCS
Hot Topics at SABCS 2017
Hope S. Rugo, MD
Conference Correspondent  in Breast Cancer, Video, SABCS
HER2+ Breast Cancer and CDK4/6 Inhibitors
Hope S. Rugo, MD
Conference Correspondent  in Breast Cancer, Video, SABCS
Disease Progression with a CDK4/6 Inhibitor plus an Aromatase Inhibitor
Hope S. Rugo, MD
Conference Correspondent  in Breast Cancer, Video, SABCS
What Differentiates Abemaciclib, Ribociclib, and Palbociclib?
Hope S. Rugo, MD
Conference Correspondent  in Breast Cancer, Video, SABCS
Why CDK4/6 Inhibitors Are Effective in HR-Positive Metastatic Breast Cancer
Hope S. Rugo, MD
Conference Correspondent  in Breast Cancer, Video, SABCS
Last modified: December 5, 2017
 
  • Privacy Policy
  • Terms of Use
  • Home
  • About
  • Subscribe
  • Advertise
  • Contact Us

©2021 Green Hill Healthcare Communications, LLC, an affiliate of The Lynx Group. All rights reserved.
1249 South River Road - Suite 202, Cranbury, NJ 08512

  • Home
  • Issues
    • 2020
      • November 2020, Vol 13, No 6
      • September 2020 - Vol 13 no 5
      • July 2020 - Vol 13 no 4
      • May 2020 - Vol 13 no 3
      • March 2020 - Vol 13 no 2
      • January 2020 - Vol 13 No 1
    • 2019
      • November 2019 - Vol 12 No 4
      • August 2019 - Vol 12 No 3
      • May 2019 - Vol 12 No 2
      • February 2019 - Vol 12 No 1
    • 2018
      • November 2018 - Vol 11 No 3
      • August 2018 - Vol 11 No 2
      • May 2018 - Vol 11 No 1
    • Issue Archive
  • Special Issues
    • Supplements
    • Guide to New FDA Approvals
      • 2019 Fourth Annual Guide
      • 2018 Third Annual Guide
      • 2017 Second Annual Guide
      • 2016 First Annual Guide
  • Categories
  • Conference Correspondent
    • Year End Review 2019
  • Web Exclusives
    • Ovarian Cancer Overview
    • All Web Exclusives
    • Drug Updates
    • FDA Approvals, News & Updates
    • In the News
    • Interview with the Innovators
    • Press Releases
    • Online First
    • Media Library
      • Videos
      • Audiocasts
  • Quick Quiz
  • CE
  • About
    • About TOP
    • Advertise
    • Editorial Board
    • Contact Us
    • Resources
    • Submit
      • Author Guidelines